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Minor group human rhinoviruses (HRVs) use members of the low-density lipoprotein receptor family for cell entry. To
investigate the utility of receptor fragments as viral inhibitors, various polypeptide segments derived from the ligand binding
domain of human very-low-density lipoprotein receptor (VLDLR) were expressed in a soluble form in bacteria. Whereas none
of the fragments was active in virus binding immediately after recovery from the cell lysates, constructs encompassing
complement type repeats 1-3, 1-6, and 1-8 spontaneously acquired virus binding activity by incubation at 4°C in buffer
containing Ca21 ions and lacking any redox system. When immobilized receptor-associated protein (RAP), a specific
chaperone for VLDLR, was present during the incubation, the yield of protein active in ligand binding was substantially
increased. A VLDLR fragment with repeats 4–6 failed to bind virus; however, it bound RAP. Bacterial expression of truncated
VLDLR 1-3 at high yield, easy purification, and folding together with high inhibitory activity toward HRV2 makes this protein
a promising starting point for the development of an oligopeptide-based antiviral agent. Using sucrose density gradient
centrifugation, we demonstrate the formation of virus–receptor complexes. The recombinant receptors can thus be used for
structure determination by electron cryo-microscopy. © 2000 Academic PressINTRODUCTION
About 50% of all common cold infections are caused
by human rhinoviruses (HRVs), members of the picorna-
virus family (Gwaltney, 1975). These are small (about 30
nm in diameter) icosahedral particles composed of 60
copies each of four capsid proteins constituting the viral
shell. The genome is a single-stranded RNA with positive
(messenger sense) polarity of about 7200 nucleotides in
length (Rueckert, 1996). The family Rhinoviridae is di-
ided into two groups. Major group viruses (91 sero-
ypes) attach to human intercellular adhesion molecule 1
ICAM-1) (Greve et al., 1989; Staunton et al., 1989; To-
assini et al., 1989) and minor group viruses (10 sero-
ypes) bind to low-density lipoprotein receptor (LDLR), to
DLR related protein (LRP), and to very-low density li-
oprotein receptor (VLDLR) (Hofer et al., 1994; Marlovits
et al., 1998b). HRV87 uses another glycosylated mem-
brane protein of unknown function for cell entry (Unca-
pher et al., 1991). Based on the susceptibility toward a
panel of antiviral substances and the available sequence
information, the International Committee for the Taxon-
omy of Viruses has recently divided the rhinoviruses into
1 Current address: Lambda, Labor fu¨r Molekularbiologische DNA-
nalysen Ges.m.b.H., Industriestrasse 6, A-4240 Freistadt, Austria.
2 Current address: Department of Molecular Biophysics and Bio-
chemistry, Yale University Medical School, 333 Cedar Street, P.O. Box
208024, New Haven, CT 06520.3 To whom correspondence and reprint requests should be ad-
dressed. Fax: (1) 43 1 42 77 9616. E-mail: dieter.blaas@univie.ac.at.
541genus A and genus B (Andries et al., 1990; King et al.,
2000). Drug binding appears to be strongly related to the
shape of a hydrophobic pocket in the viral capsid, which
determines how well the compounds are being accom-
modated (Andries et al., 1991); members of one genus
have a similar pocket geometry.
Soluble recombinant ICAM-1 has been shown to
inhibit major receptor group rhinovirus infection by
competition with cellular receptors and by inducing
viral capsid modifications resulting in subviral parti-
cles sedimenting at 135S or 80S. The former lack the
innermost capsid protein VP4, whereas the latter par-
ticles, which are considered the remainders of the
uncoating process, in addition lack the genomic RNA
(Casasnovas and Springer, 1994; Greve et al., 1991;
Hooverlitty and Greve, 1993; Korant et al., 1972). Re-
combinant ICAM-1 without the transmembrane region
and the cytoplasmic C-terminus as well as chimeric
ICAM-1 molecules composed of immunoglobulin con-
stant regions fused to the N-terminal two domains of
human ICAM-1 have been shown to be potent viral
inhibitors both in vitro (Martin et al., 1993) and in vivo
as demonstrated by clinical trials and animal experi-
ments (Huguenel et al., 1997; Turner et al., 1999).
Although about 90% of the HRV serotypes might re-
spond to ICAM-1 treatment, all minor receptor group
rhinoviruses belong to antiviral group B (genus rhino-
virus B), whose members cause disease more often
than members of group A (Andries et al., 1990). It thus
appears necessary to develop compounds active
0042-6822/00 $35.00
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542 RONACHER ET AL.against minor group viruses in order to extend and
complement a possible ICAM-1 medication.
The ligand binding domains of members of the LDLR
gene family are all composed of different numbers of
incomplete direct complement type A repeats (DiScipio
et al., 1984) of about 40 amino acids in length, each
containing six cysteines that are all involved in disulfide
bonds. LDLR has 7 such repeats (Yamamoto et al., 1984),
and VLDLR has 8 repeats (Takahashi et al., 1992; see Fig.
1 for a schematic representation of this molecule) and
LRP has clusters of 2, 8, 10, and 11 (Herz et al., 1988)
repeats (for a review on the LDLR gene family see, e.g.,
Gliemann (1998); Strickland et al. (1995)). The ligand
binding domain is followed by a region with similarity to
epidermal growth factor precursor, a highly O-glycosy-
lated domain, the transmembrane domain, and a C-
terminal intracellular region that contains internalization
signals. Using eukaryotic expression in Sf9 insect cells
of LDL minireceptors encompassing less than the seven
complement type A repeats, we recently determined the
minimal structure requirements for virus recognition and
cell protection. LDLR fragments with more than two re-
peats were able to protect HeLa cells against infection
with the minor group rhinovirus HRV2, whereas two re-
peats were sufficient for recognition of the virus in a
ligand blot-type assay (Marlovits et al., 1998a). Appar-
ently, the affinity of the smallest minireceptors was insuf-
ficient for competition with the cellular receptors when
free in solution but increasing the avidity by immobiliza-
tion on PVDF membranes allowed for attachment of the
virus over multiple sites. In contrast to ICAM-1, LDL
receptors do not uncoat minor group HRVs in vitro and
their cell protection activity thus appears to rely solely on
competition with the cellular receptors (Gruenberger et
al., 1995) or on aggregation (Marlovits et al., 1998c).
Earlier experiments with the detergent-solubilized
chicken homologue of mammalian VLDLR suggested
that this receptor might bind virus with higher affinity
than LDLR (Gruenberger et al., 1995); complexes be-
tween virus and this receptor could be isolated on su-
crose density gradients, whereas this was not possible
with soluble recombinant LDLR. The latter recombinant
protein with seven ligand binding repeats was shown
rather to induce aggregation most probably via oligo-
FIG. 1. Schematic drawing of the structure of the very-low-density
lipoprotein receptor.meric forms present in the preparation (Marlovits et al.,
1998c). With the aim of engineering a small receptorderivative efficient in cell protection and thus suitable as
a starting point for the development of an antivirally
active oligopeptide we set out to express soluble frag-
ments derived from human VLDLR. As already seen for
soluble LDL minireceptors (Marlovits et al., 1998a), ex-
pression in the baculovirus system revealed that the
entire ligand binding domain of VLDLR could be easily
purified making use of a hexa-his tag appended at its
C-terminus. Nevertheless, upon subsequent enrichment
of the correctly folded form by affinity chromatography on
columns containing the common ligand of all members
of the LDLR gene family, receptor-associated protein
(RAP) (Medh et al., 1995), we discovered that only small
amounts of the total protein were active in ligand binding
(Marlovits et al., 1998b).
Recently, it was shown that single LDLR repeats (Bieri
et al., 1995; Daly et al., 1995a, b), a two-repeat oligopep-
tide (Bieri et al., 1998), a fragment encompassing three
repeats (C5-C7) from LRP (Vash et al., 1998), and even
the entire ligand binding domain of LDLR (Simmons et
al., 1997) could be expressed in bacteria and refolded
from the completely denatured form to native structures
using a complicated protocol. This prompted us to at-
tempt bacterial expression and folding of truncated hu-
man VLDLR. Employing the expression system that
makes use of fusion of the foreign polypeptides with
maltose binding protein (MBP) we discovered that the
proteins folded spontaneously upon storage at 4°C with-
out the need for complex denaturing/renaturing proto-
cols. Furthermore, the yield of active soluble VLDLR
minireceptors was greatly improved when folding was
carried out in the presence of Sepharose-immobilized
glutathione S-transferase RAP (GST–RAP). We here re-
port on the prokaryotic expression, purification, and fold-
ing of various recombinant VLDLR fragments and dem-
onstrate their antiviral activity toward HRV2 in vitro by
protection of HeLa cells against viral infection. In addi-
tion we show that complexes between virus and recom-
binant receptor fragments containing the ligand binding
domain only are stable enough to be purified on sucrose
density gradients. This opens the way for the determina-
tion of the three-dimensional structure of these com-
plexes and will allow the identification of the receptor
binding site by electron microscopy techniques.
RESULTS
Expression of soluble human VLDLR fragments
The cDNAs encoding VLDLR fragments containing re-
peats 1-3, 4-6, 1-6, and 1-8 were excised from the re-
spective pTM1 clones together with the sequence en-
coding his6 and inserted into pMalc2b (see Table 1).
Following induction and lysis of bacteria harboring the
plasmids, high-speed supernatants were prepared and
analyzed in parallel with the pellets for the presence of
the recombinant proteins by sodium dodecyl sulfate-
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543BACTERIALLY EXPRESSED VLDL-RECEPTOR INHIBITS HRV2polyacrylamide gel electrophoresis (SDS–PAGE) under
reducing conditions. This revealed that more than 90% of
the proteins were present in the soluble fraction (data
not shown). The receptor fragments were thus purified
from the supernatants on Ni-NTA (Ni21 nitrilotriacetic
cid) resin without requiring solubilization. Aliquots cor-
esponding to 0.1 ml of bacterial culture were then ana-
yzed by SDS–PAGE under reducing conditions followed
y Coomassie brilliant blue staining. As seen in Fig. 2, all
roteins were expressed with similar yields and showed
pparent Mrs somewhat higher than those calculated
from the amino acid sequence (Table 2).
To test for the presence of correctly folded proteins,
SDS–PAGE was repeated under nonreducing conditions
followed by electrophoretic transfer of the separated
proteins to a PVDF membrane. The membrane was then
incubated with 35S-labeled HRV2 and exposed to X-ray
film. In contrast to VLDLR1-8 and other receptor fragments
xpressed in Sf9 insect cells (Marlovits et al., 1998b; and
npublished results), all bacterially produced proteins
acked ligand binding activity (data not shown). However,
hen the samples were kept at 4°C and the analysis
as repeated 3 days later, all VLDLR fusion proteins,
xcept MBP-VLDLR4-6, turned out to bind HRV2 (Fig. 3A).
s all recombinant receptor fragments were found to
T
Name of primer Sequence (59 3
TIM371 ATGCGGATCCAGGGAGAAAAGCCA
TIM522 GCAGCCCGGGATTGCCACAGTTTTC
TIM435 CTATGCGGATCCAATAACATGTAGT
TIM436 GCAGCCCGGGAGAGGGACAGTTGA
TIM372 GCTGCCCGGGACACTCTTTCAGGGG
a Nucleotides shown in boldface type are not complementary to the
underlined).
b Numbers given correspond to the position of complementarity to h
c See also Marlovits et al. (1998b).
FIG. 2. Bacterial expression of human VLDLR fragments fused to
maltose-binding protein and carrying a hexa-his tag at their C-termini.
E. coli TB1 harboring the respective plasmids were induced with IPTG
and bacterial lysates were prepared. Recombinant proteins from 0.1 ml
of bacterial culture were purified by Ni-NTA metal chelate chromatog-
raphy and separated under reducing conditions on a 12% polyacryl-
amide gel in the presence of SDS. Proteins were stained with Coo-
massie brilliant blue. Complement type A repeats contained in the
respective proteins are indicated at the top of the lanes. Apparent
relative molecular mass (kDa) of marker proteins run on the same gel
is also shown.ind GST–RAP, the two ligands appear to have different
tructure requirements for recognition (Fig. 3B). Coomas-
ie staining of a gel run in parallel with identical samples
howed that all proteins were present at comparable
mounts (Fig. 3C). In some experiments, dimers, which
lso bound both virus and RAP, were observed in small
mounts (see, e.g., first lane in Fig. 3A). Dimers arising
rom intermolecular disulfide bonds have been observed
reviously for LDLR fragments expressed in insect cells
Marlovits et al., 1998c). Using MBP-VLDLR1-6 as an ex-
mple, the time course of the folding reaction was then
nvestigated.
pontaneous folding of human VLDLR1-6
Immediately after elution from the Ni-NTA column, an
aliquot of MBP-VLDLR1-6 corresponding to 0.1 ml of bac-
terial suspension was frozen at 220°C. The remainder
was then left at 4°C, and at the times indicated in Fig. 4
samples were taken and kept frozen at 220°C until
analysis by PAGE under nonreducing conditions fol-
lowed by transfer to PVDF membranes and ligand blot-
ting with radiolabeled HRV2. As seen on the autoradio-
graph (Fig. 4), virus binding activity was absent for up to
Locationb
Gc 82–100, upstream of repeat 1
CTTCTCC 497–523, downstream of repeat 3
CGAGTTCACC 524–550, upstream of repeat 4
TCACTGCC 868–895, downstream of repeat 6
Tc 1046–1066, downstream of repeat 8
cDNA but were added to create restriction sites for BamHI or XmaI
VLDLR cDNA. For orientation, the repeat number is also indicated.
TABLE 2
Name of
recombinant
proteina
From AA No. to AA No.
of human VLDLR Calculated Mr
b
MBP-VLDLR1-3 28–151 59,000
MBP-VLDLR1-6 28–274 72,000
MBP-VLDLR1-8 28–355 81,000
MBP-VLDLR4-6 152–274 59,000
runcated MBPc 43,000
a Subscripts refer to the repeats contained.
b Including the oligopeptide sequence ISEFADP N-terminal of the
VLDLR fragment and the peptide sequence PGLQSRPGGPGQGSGGH-
HHHHH C-terminal of the VLDLR fragment, but excluding the leader
peptide; calculations also include MBP and the cleavage site for factor
Xa.ABLE 1
39)a
AATGT
TTCAT
CCCGA
CCTCA
CTCA
VLDLRc The MBP encoded in the vector is truncated at the C-terminus and
contains amino acids encoded in the multiple cloning site.
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544 RONACHER ET AL.1 h after elution from the column, but appeared at about
6 h and continually increased with time. Moreover, at
early time points virus bound preferentially to high-mo-
lecular-weight aggregates of the receptor protein but the
amount and virus binding activity of the monomeric form
increased over the time of incubation.
Folding of recombinant MBP-VLDLR fragments
assisted by immobilized GST–RAP
RAP has been shown to act as a molecular chaperone
for members of the LDLR family presumably by prevent-
ing aggregation of the receptors with their ligands in the
endoplasmic reticulum (Bu et al., 1995; Willnow et al.,
995). In addition, together with Ca21 ions, it is required
for proper folding of LRP (Obermoeller et al., 1998) and of
VLDLR (Sato et al., 1999). We thus argued that folding
might be promoted in the presence of RAP. Therefore,
Ni-NTA purified MBP-VLDR fragments were incubated
with GST–RAP Sepharose at 4°C for 3 days under gentle
agitation. As correctly folded protein was expected to
remain bound to the resin, it was then poured into a
FIG. 3. After spontaneous folding, MBP-VLDLRs bind 35S-labeled
HRV2 (A) and biotinylated GST–RAP (B) in ligand blots. Following
elution of the recombinant proteins from Ni-NTA columns they were
allowed to fold by incubation at 4°C for 3 days. Samples corresponding
to 0.1 ml of bacterial culture were applied to SDS 12% polyacrylamide
gels, separated under nonreducing conditions, and transferred to PVDF
membranes for ligand blotting. To monitor the total amount of protein,
an identical gel was also stained with Coomassie brilliant blue (C).
Positions and corresponding relative molecular mass (in kDa) of
marker proteins are also shown.
FIG. 4. Time course of folding of MBP-VLDLR1-6 fusion protein. MBP-
LDLR1-6 was purified from bacterial lysates on a Ni-NTA column.
mmediately after elution, an aliquot was frozen at 220°C and the
emainder was kept at 4°C. At the times indicated at the top of the
anes, samples were taken and kept frozen until analysis by SDS–PAGE
n 10% gels under nonreducing conditions followed by ligand blotting
ith radiolabeled HRV2. Samples correspond to 0.1 ml of bacterial
ulture. The positions of 14C-labeled marker proteins (given in kDa)
eparated on the same gel and transferred to the ligand blot are also
ndicated.column, washed with 0.5X TBS-Ca and bound protein
was eluted with 1 M NH3 in 0.5X TBS-Ca. Ammonia was
emoved and the volume was reduced by a factor of 2 in
Speedvac concentrator. In order to estimate the frac-
ion of correctly folded material contained in the total
rotein expressed, aliquots from flowthrough, wash, and
luate were analyzed by PAGE followed by ligand blot-
ing with radiolabeled HRV2. As exemplified for MBP-
LDLR1-3 on the autoradiograph depicted in Fig. 5, the
raction of material active in virus binding was substan-
ially increased by this procedure. Determination of the
adioactive virus bound to the monomeric form of the
eceptor (see arrowhead) with an Instant Imager re-
ealed that the combined eluates (fractions 1 and 2 in
ig. 5) exhibited a four times higher binding activity
oward HRV2 than the corresponding material that had
een incubated in the absence of GST–RAP Sepharose
leftmost lane in Fig. 5).
irus-neutralization activity of the recombinant VLDLR
ragments
Having demonstrated that VLDLR fragments could be
asily expressed in bacteria and spontaneously folded
ithout the need for tedious denaturation/refolding pro-
ocols we determined the cell protection activity of the
ecombinant fusion proteins toward the minor group rhi-
ovirus HRV2 following the procedure previously used
or LDL minireceptors (Marlovits et al., 1998a). Briefly, 100
CID50 of HRV2 was incubated with twofold serial dilu-
tions of the Ni-NTA purified receptors that had been
folded in the presence of GST–RAP as pointed out above,
FIG. 5. RAP-assisted folding of MBP-VLDLR1-3 fusion protein. MBP-
VLDLR1-3 was purified from bacterial lysates on a Ni-NTA column. Three
undred microliters of GST–RAP–Sepharose was added to 1 ml (0.8
g) of the eluate and the sample was incubated at 4°C under gentle
ixing for 3 days. The resin was pelleted and the supernatant (S) was
ollected. After being washed with 500 ml of 0.5X TBS-Ca (W), bound
protein was eluted with 2X 100 ml of 1 M NH3 in 0.5X TBS-Ca (F1 and
F2). Aliquots corresponding to 1/20 of the original volume were ana-
lyzed for ligand binding by separation of the proteins on SDS 12%
polyacrylamide gels run under nonreducing conditions. The proteins
were transferred to PVDF membranes and virus binding activity was
visualized by incubation with 35S-labeled HRV2 followed by exposure to
-ray film for 1 day. For comparison, the original sample was incubated
n the absence of GST–RAP–Sepharose (2). The monomeric form of
BP-VLDLR1-3 is indicated with an arrowhead.and the mixtures were transferred onto HeLa cell mono-
layers grown in 96-well microtiter plates. After 5 days of
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545BACTERIALLY EXPRESSED VLDL-RECEPTOR INHIBITS HRV2incubation at 34°C, cells remaining bound to the plastic
were stained with Amido black. The stain was then
dissolved in NaOH and quantified with a microplate
reader (Marlovits et al., 1998c). The minimal inhibitory
concentrations, affording 50% protection of the cell
monolayer (MIC50 (Arruda et al., 1992)), were compared
ith those of LDL minireceptors (Marlovits et al., 1998a).
rom this it becomes clear that rLDLR3-7h was most
ctive against HRV2 closely followed by MBP-VLDLR1-6.
From the smallest minireceptors, MBP-VLDLR1-3 was
found to be more active than rLDLR3-5h (Table 3). Similar
esults were also obtained with another minor group
irus, HRV1A; the major group virus HRV14, used as a
ontrol, was not inhibited (data not shown). Due to the
arge number of possible combinations of the repeats
resent in LDLR and VLDLR it is not possible to rule out
he possibility that another combination of the repeats
resent in these receptors would be even more active in
ell protection against minor group virus infection.
hether the cell protective activity is directly related to
he affinity of the receptor derivatives for the virus is
urrently being investigated using plasmon surface res-
nance technology.
ormation of complexes between virus and receptor
Various attempts to isolate complexes between HRV2
nd recombinant LDL receptor fragments have failed,
ost probably due to extensive aggregation (Marlovits et
l., 1998c) or too low affinity (Marlovits et al., 1998a).
lthough virus/receptor complexes formed between
RV2 and detergent solubilized OVR (Gruenberger et al.,
995) they could not be visualized by electron micros-
opy (unpublished results). We therefore asked whether
ecombinant human VLDL receptors were able to asso-
iate with the virus in solution and assemble complexes
TABLE 3
Recombinant soluble
receptora
Number of
repeats
MIC50
(nmol/liter)b
rLDLR3-5h 3 180
rLDLR3-7h 5 12
rLDLR1-5h 5 69
rLDLR1-7h 7 62
MBP-VLDLR1-3 3 79
MBP-VLDLR4-6 3 Inactive
MBP-VLDLR1-6 6 16
MBP-VLDLR1-8 8 n.d.
c
a Values for recombinant LDLR fragments were taken from Marlovits
t al. (1998a) and converted to nmol/liter.
b Values were obtained from a cell protection assay by determination
of A560 after the stain was dissolved in 100 ml of 1 M NaOH as described
previously (Marlovits et al., 1998c).
c Not determined.table enough to be separated from excess receptor by
ucrose density gradient centrifugation. Assuming 60
t
seceptor binding sites, HRV2 was incubated with a three-
old molar excess of MBP-VLDLR1-8 and the mixture was
applied onto sucrose gradients formed in 800-ml centri-
fuge tubes. After ultracentrifugation, tubes were pierced
at the bottom and fractions corresponding to two drops
each were collected. Proteins present in the fractions
were then determined by polyacrylamide gel electro-
phoresis followed by Coomassie brilliant blue staining.
As seen from the presence of the viral capsid proteins
VP1–VP3, virus alone sedimented to the lower third of the
gradient under these conditions (Fig. 6A). When the mix-
ture of virus and receptor was analyzed under identical
conditions, the receptor was found to comigrate with the
virus at a position somewhat shifted toward the lower
density of the gradient (Fig. 6B). This indicates that the
sedimentation coefficient of the complex is slightly less
than that of the virus alone, which sediments at 150S
(Korant et al., 1972). Finally, receptor alone does not enter
the gradient at all in the absence of virus, which indi-
cates the absence of aggregates and excludes acciden-
tal comigration (Fig. 6C).
FIG. 6. Sucrose density gradient centrifugation reveals the formation
of complexes between HRV2 and MBP-VLDLR1-8. Virus was incubated
ith receptor for 1 h at room temperature and applied onto sucrose
ensity gradients formed in 800-ml centrifuge tubes. After centrifuga-
ion, fractions collected from the bottom (left) were analyzed by SDS–
2% polyacrylamide gel electrophoresis and Coomassie brilliant blue
taining. (A) Virus incubated without receptor; (B) virus incubated with
eceptor; (C) receptor without virus. Positions of marker proteins run on
he same gels are indicated on the right. Note that the gradients had a
igmoid shape as determined with a refractometer.
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546 RONACHER ET AL.DISCUSSION
We have shown earlier that LDL minireceptors with
ell protective activity against minor group HRV infection
ould be expressed in the baculovirus system (Marlovits
t al., 1998a). However, although the amount of total
rotein was rather high, we observed that only a small
raction was present in a correctly folded state, requiring
igand affinity chromatography as an additional means of
nriching for the protein active in ligand recognition
Marlovits et al., 1998a). For this purpose, a ligand of
LDLR, rabbit b-VLDL, was used. However, production of
his lipoprotein is not as reproducible as that of recom-
inant GST–RAP, which has low affinity toward LDLR but
ery high affinity toward VLDLR (Medh et al., 1995). GST–
RAP Sepharose was thus used for purification of a re-
combinant soluble VLDLR fragment encompassing the
entire ligand binding domain (repeats 1–8) expressed in
Sf9 insect cells. This fragment was shown to be active in
protection of HeLa cells against infection with HRV2
(Marlovits et al., 1998b). In order to investigate the activity
of smaller VLDLR fragments with respect to cell protec-
tion against minor group rhinovirus infection, expression
of soluble VLDLRs in bacteria was attempted. Whereas
LDLR contains three potential glycosylation sites, VLDLR
has only one; this site is located exactly at the border
between repeat 3 and repeat 4 and is thus not contained
in the receptor fragments VLDLR1-3 and VLDLR4-6. There-
fore, we argued that expression in bacteria would more
easily result in active proteins than in the case of the
LDLR fragments where glycosylation might be required
for correct folding. We thus investigated the utility of the
pMal system for bacterial expression of the desired pro-
tein as a fusion to maltose binding protein. The commer-
cial plasmid pMalc2x was modified by introduction of a
novel multiple cloning site and a hexa-histidine tag that
becomes appended at the C-terminus of the recombi-
nant protein upon expression under the control of the
strong tac promoter. However, all recombinant VLDL
receptor fragments turned out to be inactive in virus
binding when tested immediately after elution from the
Ni-NTA column but acquired virus binding activity upon
storage at 4°C within 1 to 2 days. This occurred concom-
itantly with the rearrangement of disulfide bonds as high-
molecular-weight oligomers gradually disappeared, giv-
ing rise to monomeric forms of the proteins. We have not
investigated folding of the VLDLR fragments in the ab-
sence of MBP. Therefore, the possibility cannot be ex-
cluded that this particular fusion partner takes a major
role in folding or in rendering the fragments more solu-
ble. Recently, Kapust and colleagues compared the sol-
ubility of foreign proteins upon fusion to MBP, thiore-
doxin, and glutathione S-transferase, respectively, upon
expression in Escherichia coli and found the former to beost effective (Kapust and Waugh, 1999).
As RAP was shown to act as a chaperone for membersf the LDLR gene family (reviewed by Bu and Schwartz
1998)) we argued that its presence would promote the
olding process. Incubation of the column eluates with
epharose-immobilized GST–RAP indeed resulted in a
ubstantial increase in virus binding activity and at the
ame time allowed for additional purification as only
orrectly folded material remained bound to the column
aterial and was subsequently eluted. So far, the small-
st VLDLR fragments investigated are VLDLR1-3 and
VLDLR4-6; whereas the former was found to be active in
a cell protection assay, the latter was not.
Our results are at variance with those of a recent
report by Savonen et al. (1999), who presented evidence
for the binding site of RAP residing in the first three
repeats of VLDLR. We found that both MBP-VLDLR1-3 and
MBP-VLDLR4-6 were retained on the GST–RAP column
and that both bound biotinylated GST–RAP on ligand
blots as well. This clearly demonstrates the presence of
more than one RAP binding site on the native receptor.
Comparison of MBP-VLDLR1-3 with the LDL minirecep-
or rLDLR3-5h revealed a higher cell protection activity of
the former protein. Whereas the N-termini of the recom-
binant LDL minireceptors were identical to that of the
native receptor, the bacterially expressed VLDLR frag-
ments investigated were N-terminally fused to MBP. It is
thus interesting to note that this fusion had no major
influence on virus binding as seen upon enzymatic re-
moval of MBP with factor Xa (data not shown). This
leaves us with the question of how the interaction be-
tween virus and receptor takes place. In major group
viruses, the N-terminal immunoglobulin-like domain of
ICAM-1 binds within the canyon, a deep cleft encircling
the fivefold axes of icosahedral symmetry of the viral
capsid (Olson et al., 1993). It thus appears unlikely that
receptors carrying MBP as an N-terminal extension of 43
kDa can be accommodated within an equivalent posi-
tion. Based on the above findings it appears probable
that the receptors attach to sites more exposed than the
interior of the canyon. Nevertheless, a more inclined
position, similar to that of the poliovirus receptor, whose
interactions with the virus extend beyond the canyon
(Belnap et al., 2000; He et al., 2000; Xing et al., 2000),
might permit lateral contacts, keeping the N-terminally
fused MBP free to stick out in solution.
The number of repeats present in LDLR and VLDLR
and their difference in sequence preclude an analysis of
all imaginable combinations. It is thus possible that re-
ceptor fragments with three or even two repeats exhibit
higher cell protective activity. The comparison between
VLDLR1-3 and VLDLR4-6 suggests, however, that particular
combinations of the repeats determine viral binding af-
finity. Nevertheless, the possibility cannot be excluded
that artificial combinations, such as oligomers assem-
bled from the same repeat, can act as potent viral inhib-
itors as well. In conclusion, the simplicity of expression,
folding, and purification of MBP-VLDLR1-3 is highly sug-
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547BACTERIALLY EXPRESSED VLDL-RECEPTOR INHIBITS HRV2gestive for its use as a starting point for the development
of an antivirally active drug as preliminary data indicate
that the maltose binding protein moiety can easily be
removed by cleavage with factor Xa without loss of cell
protection activity. Experiments aimed at increasing the
affinity of this receptor fragment for minor group HRVs by
mutagenesis and selection will be carried out in the
future.
Many attempts to isolate stable complexes between
HRV2 and various recombinant LDLR fragments have
been unsuccessful. We think that the affinity of LDLR or
of the fragments thereof is too low for the components to
remain associated during the separation process such
as sucrose density gradient centrifugation or spin col-
umn separation (Hewat and Blaas, 1996). Nevertheless,
the receptor fragments proved very active in protecting
the cells against viral infection (Table 3). Similar obser-
vations have also been made with recombinant decay
accelerating factor and echovirus 7 (Powell et al., 1997).
MBP-VLDLR1-8 (Fig. 6) and VLDLR1-3 (to be published
lsewhere) have now been shown to attach sufficiently
trongly to HRV2 to allow for the isolation of complexes.
nalysis of these complexes by electron cryo-micros-
opy followed by image reconstruction is now under way.
MATERIALS AND METHODS
aterials
All chemicals were purchased from Sigma, unless spec-
fied otherwise. Isopropylthio-b-D-galactoside (IPTG) and
etal calf serum were obtained from Life Technologies. Pfu
olymerase was from Stratagene; restriction enzymes, T4-
NA ligase, pMalc2x, and bacterial strain TB1 were from
ew England Biolabs. Ni-NTA beads were from Qiagen.
ST–RAP was prepared as described (Herz et al., 1991) and
ovalently linked to CNBr-activated Sepharose following
he manufacturer’s protocol (Amersham Pharmacia Bio-
ech). About 4.5 mg of GST–RAP per milliliter of settled
epharose beads was bound as determined by the modi-
ied Lowry procedure (Cadman et al., 1979). HRVs were
rom the American Type Culture Collection. Rhino HeLa
ells (Flow Laboratories) were used throughout. HRV2 was
etabolically labeled with [35S]cysteine and [35S]methi-
onine (ARS110, American Radiolabeled Chemicals) as de-
scribed (Neubauer et al., 1987). 14C-labeled marker proteins
ere from Amersham Life Sciences. Polyvinylidene difluo-
ide (PVDF) membranes were from Millipore. Sulfosuccin-
midyl 6-(biotinamido) hexanoate (NHS-LC-biotin) and alka-
ine phosphatase conjugated streptavidin were purchased
rom Pierce. Nitro-blue tetrazolium chloride (NBT) was from
mresco and dissolved in 70% dimethyl formamide at 50
g/ml. 5-Bromo-4-chloro-3-indolyl-phosphate, disodiumalt (BCIP) was from Calbiochem and dissolved at 50
g/ml in water.loning and expression of soluble VLDLR fragments
Following the protocol described previously for the
onstruction of recombinant baculovirus vVLDLR1-8h con-
aining the entire ligand binding domain (Marlovits et al.,
998b), combinations of the synthetic oligonucleotide
rimers listed in Table 1 were used for PCR amplification
f cDNA fragments encompassing complement type A
epeats 1-3, 4-6, and 1-6 from pVLDLR-1 (Sakai et al.,
994). For completeness, primers used previously for
mplification of repeats 1–8 are also included in Table 1.
fter digestion with BamHI and XmaI, the DNAs were
urified by agarose gel electrophoresis and adsorption
o glass milk; eluted DNA was then ligated into the
ransposition vector pTM1 to also allow for use of the
aculovirus expression system (Marlovits et al., 1998a).
or bacterial expression of VLDLR fragments with MBP
used to their N-termini, pMalc2x was modified by remov-
ng the multiple cloning site by digestion with EcoRI and
indIII and introduction of a new polylinker sequence
esulting from ligation with a double-stranded linker DNA
btained by annealing synthetic oligonucleotides with
he sequences 59-AATTCGCGGATCCCCATGGGGTA-
CA-39 and 59-AGCTTGGTACCCCATGGGGATCCGCG-39.
he resulting vector was termed pMalc2b and used for
ll following constructions. The cleavage site for factor
a encoded in pMalc2x was conserved. The new vector
hus created allowed for the direct introduction of BamHI
nd KpnI fragments excised from the respective TM1
onstructs (see above) together with the hexa-his tag
equence (see Table 1).
E. coli TB1 were transformed with the respective plas-
ids and induced at a density corresponding to A600 of
0.8 with 0.4 mM IPTG at 30°C for 2 h. Cells were pelleted,
suspended in 25 mM Tris–HCl (pH 7.4), 150 mM NaCl, 2
mM CaCl2 (TBS-Ca; 5 ml per 1 g of moist pellet) contain-
ng 1 mM phenylmethylsulfonyl fluoride, and broken by
onication. Insoluble material was removed by centrifu-
ation at 18 krpm for 30 min using an SS34 fixed angle
otor in a Sorvall centrifuge, and the recombinant pro-
eins corresponding to 5 ml of bacterial lysate were
urified over a 2-ml Ni-NTA column. VLDLR fragments
ere termed MBP-VLDLRn-m with the subscripts referring
o the repeats contained. The segments from native
uman VLDLR present in the recombinant proteins and
heir calculated relative molecular mass are summarized
n Table 2.
igand blotting
Ligand binding activity of the purified fusion proteins
as revealed with HRV2 metabolically labeled with
35S]methionine/[35S]cysteine (Neubauer et al., 1987) after
SDS–PAGE under nonreducing conditions and electro-
phoretic transfer to PVDF membranes as described pre-
viously (Marlovits et al., 1998c). Bound virus was visual-
ized by autoradiography on Kodak Biomax film. RAP
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548 RONACHER ET AL.binding to recombinant receptor molecules was moni-
tored using biotinylated GST–RAP.
Recombinant GST–RAP was dialyzed against PBS, and
NHC-LC-biotin, dissolved in DMSO, was added in a
100-fold molar excess. After incubation for 3 h at 4°C the
reaction was quenched by addition of 1/10 vol of 1 M
Tris–HCl (pH 9) and the material was dialyzed against
TBS-Ca. To monitor RAP binding, the membrane was
incubated with biotinylated GST–RAP at 1 mg/ml followed
y a 1:10,000 dilution of streptavidin–AP conjugate.
ound streptavidin was detected with 66 ml NBT and 33
ml BCIP stock solution per 10 ml of AP buffer (100 mM
Tris–HCl (pH 9.6), 100 mM NaCl, 5 mM MgCl2). Blocking
and washing of the membranes with 2 and 0.1% Tween
20, respectively, were carried out as described for HRV2
(Marlovits et al., 1998c).
Folding of MBP-VLDLRn-m
After elution from the Ni-NTA metal chelate column the
samples were stored at 4°C without further treatment. At
different time periods, aliquots were removed and frozen
until all samples were subjected simultaneously to PAGE
under nonreducing conditions. Proteins were transferred
onto PVDF membranes and virus binding activity was
revealed by incubation with 35S-labeled HRV2. In parallel,
n identical gel was stained with Coomassie brilliant
lue. For RAP-assisted folding, 4 ml of the metal chelate
olumn eluates (12 mg total protein) was added to 6 ml
f settled GST–RAP Sepharose. The suspension was
ixed by slowly rotating the tube end over end in the
old room. After 2 days the gel was transferred into a
olumn, the liquid was drained, the column material was
ashed with 30 ml of 0.5X TBS-Ca, and bound protein
as eluted with 4 ml of 1 M NH3 in 0.5X TBS-Ca. NH3 was
removed and the samples were concentrated two times
in a Speedvac concentrator.
Cell protection assays
Cell protection assays were carried out as de-
scribed previously (Marlovits et al., 1998c). Briefly,
HRV2 at 100 TCID50 was incubated in infection medium
MEM containing 2% heat-inactivated fetal calf serum
nd 30 mM MgCl2) in a final volume of 100 ml with
serial twofold dilutions of purified recombinant VLDLR
fragments for 90 min at 34°C. HeLa cell monolayers in
96-well plates were then challenged with the mixtures
and incubated for 5 days at 34°C. Media were re-
moved and cells having remained attached to the
plastic surface were stained with Amido black (0.1% in
acetic acid, methanol, water; 10/40/50 vol/vol). For
quantification, the stain was dissolved in 100 ml of 1 MaOH and A560 was determined in a microplate reader
(Marlovits et al., 1998c). CSucrose gradient centrifugation
To resolve MBP-VLDLR1-8 from any oligomers present
in the GST–RAP Sepharose column eluate the material
was run in TBS-Ca over a Superdex 200 column con-
nected to a Pharmacia FPLC system. The peak fraction
corresponding to the monomer was concentrated five
times in a Speed Vac concentrator and 60 mg MBP-
VLDLR1-8 (740 pmol) was incubated with 30 mg HRV2
(3.75 pmol) in a final volume of 50 ml for 1 h at room
temperature and was layered onto sigmoid sucrose den-
sity gradients (45–15%) formed by diffusion in 800-ml
ellulose nitrate tubes (Stone, 1974). Centrifugation was
or 80 min at 35 krpm in a Beckman SW50.1 rotor
quipped with suitable adapters. The tubes were con-
ected to a peristaltic pump at their top and pierced at
he bottom with a hypodermic needle, and two-drop
ractions were collected by slowly pumping air into the
ubes after removal of the needle. The fractions were
nalyzed by SDS–polyacrylamide gel electrophoresis on
2% minigels under reducing conditions followed by
oomassie brilliant blue staining.
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